Evolocumab and Cardiovascular Risk in High-Risk Diabetes: What VESALIUS-CV Found 8th August 2026 by Living Diabetes Editorial A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.